1. Home
  2. LXRX vs ESOA Comparison

LXRX vs ESOA Comparison

Compare LXRX & ESOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • ESOA
  • Stock Information
  • Founded
  • LXRX 1995
  • ESOA 2006
  • Country
  • LXRX United States
  • ESOA United States
  • Employees
  • LXRX N/A
  • ESOA N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • ESOA Water Sewer Pipeline Comm & Power Line Construction
  • Sector
  • LXRX Health Care
  • ESOA Industrials
  • Exchange
  • LXRX Nasdaq
  • ESOA Nasdaq
  • Market Cap
  • LXRX 124.4M
  • ESOA 135.6M
  • IPO Year
  • LXRX 2000
  • ESOA 2006
  • Fundamental
  • Price
  • LXRX $0.70
  • ESOA $9.42
  • Analyst Decision
  • LXRX Buy
  • ESOA
  • Analyst Count
  • LXRX 4
  • ESOA 0
  • Target Price
  • LXRX $3.67
  • ESOA N/A
  • AVG Volume (30 Days)
  • LXRX 5.7M
  • ESOA 155.4K
  • Earning Date
  • LXRX 05-13-2025
  • ESOA 05-20-2025
  • Dividend Yield
  • LXRX N/A
  • ESOA 0.32%
  • EPS Growth
  • LXRX N/A
  • ESOA 161.70
  • EPS
  • LXRX N/A
  • ESOA 1.44
  • Revenue
  • LXRX $31,081,000.00
  • ESOA $362,359,788.00
  • Revenue This Year
  • LXRX N/A
  • ESOA $9.95
  • Revenue Next Year
  • LXRX $84.78
  • ESOA N/A
  • P/E Ratio
  • LXRX N/A
  • ESOA $6.54
  • Revenue Growth
  • LXRX 2481.48
  • ESOA 8.42
  • 52 Week Low
  • LXRX $0.28
  • ESOA $5.70
  • 52 Week High
  • LXRX $2.45
  • ESOA $19.83
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 60.07
  • ESOA 53.18
  • Support Level
  • LXRX $0.63
  • ESOA $8.31
  • Resistance Level
  • LXRX $0.71
  • ESOA $9.91
  • Average True Range (ATR)
  • LXRX 0.07
  • ESOA 0.57
  • MACD
  • LXRX -0.00
  • ESOA 0.13
  • Stochastic Oscillator
  • LXRX 55.00
  • ESOA 71.51

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

About ESOA Energy Services of America Corporation

Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.

Share on Social Networks: